AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Tharimmune, Inc. Director's Dealing 2022

Jan 27, 2022

34824_dirs_2022-01-27_5a0f6b9c-f6b7-4610-8784-4e7c5083e6a4.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11

Reporting Person: Kaur Varinder (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	653059	Direct